Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dihydrocodeine thiocyanate is a semi-synthetic opioid analgesic and antitussive, primarily utilized for the management of moderate to severe pain and the suppression of non-productive cough. It acts as an agonist at the mu-opioid receptors ($\mu$-receptors) within the central nervous system, mimicking the effects of endogenous endorphins to produce analgesia, sedation, and cough suppression. As a derivative of codeine, dihydrocodeine exhibits approximately twice the analgesic potency. The thiocyanate salt form is commonly used in pharmaceutical formulations, particularly in Europe, and is available in various dosage forms such as oral drops and solutions. SALARAS is a notable manufacturer of this active pharmaceutical ingredient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dihydrocodeine thiocyanate.